Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. In the first part of the study, participants must have tumors that have a marker called HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks. This study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Conditions Studied
Interventions
- DRUG disitamab vedotin
Study Locations (20)
Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Gilbert
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Glendale
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Mesa
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Mesa
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Phoenix
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Scottsdale
California
- Valkyrie Clinical Trials(Additional Suite) — Los Angeles
- Valkyrie Clinical Trials — Los Angeles
- University of California Davis Comprehenvise Cancer Center — Sacramento
- University of California Davis Medical Center — Sacramento
- Providence Medical Foundation — Santa Rosa
Connecticut
- Smilow Cancer Hospital at Yale - New Haven — New Haven
- Yale-New Haven Hospital-Yale Cancer Center — New Haven
- Smilow Cancer Hospital Phase 1 Unit — New Haven
- Yale Cancer Center — New Haven
- Smilow Cancer Hospital Care Center at Trumbull — Trumbull
Florida
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables
- University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach
Colorado
- PCM Trials — Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-11-14 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06003231
The ClinicalTrials.gov registry entry for NCT06003231 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 1 intervention — of which disitamab vedotin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06003231 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Arizona, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06003231 about?
NCT06003231 is a clinical study titled "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2". This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endom...
What is the current status of trial NCT06003231?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2023-11-14. Estimated completion is 2028-05-31.
What conditions does trial NCT06003231 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Head and Neck Neoplasms, Endometrial Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06003231?
The interventions under investigation include: disitamab vedotin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06003231?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06003231 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.